OncoSec Medical Inc (ONCSQ)

[chickpea598]

Yup, but EP-IL12 is Oncosec proprietary technology. So big deal if other companies use the Bio-Marker assay. If Oncosec platform shows better results with far less severe side affects than other therapies do it is a win for Oncosec. If EP-IL 12 + PD1 yields better results than Keytruda or Opdivo monotherapy, EP-IL12 + PD1 could be used as a first-line therapy for non-responders. This represents a vastly larger number of cancer patients than the ones who respond to PD1 monotherapy which is only around a 30% response rate.....and there is big bucks down the line to treat these patients who do not respond to monotherapy.